Mesenchymal stem cells and their derived small extracellular vesicles for COVID-19 treatment

Huang, Yingna; Li, Xin; Yang, Lina

doi:10.1186/s13287-022-03034-4

Cited by 11 publications

(5 citation statements)

References 92 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…MSCs are now widely investigated in various diseases, such as kidney disease, osteoarthritis, and even COVID-19 [5,33,34]. In recent years, researchers have started to focus on the role of MSCs on PF.…”

Section: Discussionmentioning

confidence: 99%

Exosomal lnc-CDHR derived from human umbilical cord mesenchymal stem cells attenuates peritoneal epithelial-mesenchymal transition through AKT/FOXO pathway

Jiao

Huang

Sun

et al. 2023

Aging

Self Cite

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Exosomal lnc-CDHR derived from human umbilical cord mesenchymal stem cells attenuates peritoneal epithelial-mesenchymal transition through AKT/FOXO pathway

Jiao

Huang

Sun

et al. 2023

Aging

Self Cite

View full text Add to dashboard Cite

show abstract

“…The found that these stem cells were well tolerated in this severe pneumonia [179]. Similarly, the therapeutic option of MSCs in other respiratory disease patients such as COPD, ARDS and COVID-19 patients is well reported [180][181][182][183]. Interestingly, a recent phase I study assessed the tolerability and safety of allogeneic MSC infusion in cystic fibrosis patients and found that the allogeneic MSC intravenous infusions is welltolerated and safe [184].…”

Section: Most Recent Progress In the Application Of Mesenchymal Strom...mentioning

confidence: 96%

Mesenchymal stromal cell-based therapy in lung diseases; from research to clinic

Yuan

2024

Am J Stem Cells

View full text Add to dashboard Cite

Recent studies demonstrated that mesenchymal stem cells (MSCs) are important for the cell-based therapy of diseased or injured lung due to their immunomodulatory and regenerative properties as well as limited side effects in experimental animal models. Preclinical studies have shown that MSCs have also a remarkable effect on the immune cells, which play major roles in the pathogenesis of multiple lung diseases, by modulating their activity, proliferation, and functions. In addition, MSCs can inhibit both the infiltrated immune cells and detrimental immune responses in the lung and can be used in treating lung diseases caused by a virus infection such as Tuberculosis and SARS-COV-2. Moreover, MSCs are a source for alveolar epithelial cells such as type 2 (AT2) cells. These MSC-derived functional AT2-like cells can be used to treat and diminish serious lung disorders, including acute lung injury, asthma, chronic obstructive pulmonary disease (COPD), and pulmonary fibrosis in animal models. As an alternative MSC-based therapy, extracellular vesicles that are derived from MSC-derived can be employed in regenerative medicine. Herein, we discussed the key research findings from recent clinical and preclinical studies on the functions of MSCs in treating some common and well-studied lung diseases. We also discussed the mechanisms underlying MSC-based therapy of well-studied lung diseases, and the recent employment of MSCs in both the attenuation of lung injury/inflammation and promotion of the regeneration of lung alveolar cells after injury. Finally, we described the role of MSC-based therapy in treating major pulmonary diseases such as pneumonia, COPD, asthma, and idiopathic pulmonary fibrosis (IPF).

show abstract

“…The advantages of EVs from human cells or cell lines as therapeutic agents are the potential to cross biological barriers, cell-specific function, and their low immunogenicity because they do not display exogenous factors ( 84 , 85 ). The in vitro generation and modulation of mesenchymal stem cell-derived EVs for Covid-19 treatment and autoimmune diseases is currently tested in clinical and pre-clinical studies ( 86 , 87 ), with no severe adverse effects described so far. In preclinical models, MSC- or Treg-derived EVs have been successfully used in an animal model of rheumatoid arthritis ( 88 , 89 ).…”

Section: Translational Application Of Extracellular Vesicles Targetin...mentioning

confidence: 99%

Purinergic enzymes on extracellular vesicles: immune modulation on the go

Winzer,

Nguyen,

Schoppmeier

et al. 2024

Front. Immunol.

View full text Add to dashboard Cite

An increase in the extracellular concentration of ATP as a consequence of cellular stress or cell death results in the activation of immune cells. To prevent inflammation, extracellular ATP is rapidly metabolized to adenosine, which deploys an anti-inflammatory signaling cascade upon binding to P1 receptors on immune cells. The ectonucleotidases necessary for the degradation of ATP and generation of adenosine are present on the cell membrane of many immune cells, and their expression is tightly regulated under conditions of inflammation. The discovery that extracellular vesicles (EVs) carry purinergic enzyme activity has brought forward the concept of EVs as a new player in immune regulation. Adenosine-generating EVs derived from cancer cells suppress the anti-tumor response, while EVs derived from immune or mesenchymal stem cells contribute to the restoration of homeostasis after infection. Here we will review the existing knowledge on EVs containing purinergic enzymes and molecules, and discuss the relevance of these EVs in immune modulation and their potential for therapy.

show abstract

Mesenchymal stem cells and their derived small extracellular vesicles for COVID-19 treatment

Cited by 11 publications

References 92 publications

Exosomal lnc-CDHR derived from human umbilical cord mesenchymal stem cells attenuates peritoneal epithelial-mesenchymal transition through AKT/FOXO pathway

Exosomal lnc-CDHR derived from human umbilical cord mesenchymal stem cells attenuates peritoneal epithelial-mesenchymal transition through AKT/FOXO pathway

Mesenchymal stromal cell-based therapy in lung diseases; from research to clinic

Purinergic enzymes on extracellular vesicles: immune modulation on the go

Contact Info

Product

Resources

About